Usami Makoto, Miyoshi Makoto, Yamashita Hayato
Makoto Usami, Makoto Miyoshi, Hayato Yamashita, Division of Nutrition and Metabolism, Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe 654-0142, Japan.
World J Gastroenterol. 2015 Nov 7;21(41):11597-608. doi: 10.3748/wjg.v21.i41.11597.
The gut microbiota has the capacity to produce a diverse range of compounds that play a major role in regulating the activity of distal organs and the liver is strategically positioned downstream of the gut. Gut microbiota linked compounds such as short chain fatty acids, bile acids, choline metabolites, indole derivatives, vitamins, polyamines, lipids, neurotransmitters and neuroactive compounds, and hypothalamic-pituitary-adrenal axis hormones have many biological functions. This review focuses on the gut microbiota and host metabolism in liver cirrhosis. Dysbiosis in liver cirrhosis causes serious complications, such as bacteremia and hepatic encephalopathy, accompanied by small intestinal bacterial overgrowth and increased intestinal permeability. Gut dysbiosis in cirrhosis and intervention with probiotics and synbiotics in a clinical setting is reviewed and evaluated. Recent studies have revealed the relationship between gut microbiota and host metabolism in chronic metabolic liver disease, especially, non-alcoholic fatty liver disease, alcoholic liver disease, and with the gut microbiota metabolic interactions in dysbiosis related metabolic diseases such as diabetes and obesity. Recently, our understanding of the relationship between the gut and liver and how this regulates systemic metabolic changes in liver cirrhosis has increased. The serum lipid levels of phospholipids, free fatty acids, polyunsaturated fatty acids, especially, eicosapentaenoic acid, arachidonic acid, and docosahexaenoic acid have significant correlations with specific fecal flora in liver cirrhosis. Many clinical and experimental reports support the relationship between fatty acid metabolism and gut-microbiota. Various blood metabolome such as cytokines, amino acids, and vitamins are correlated with gut microbiota in probiotics-treated liver cirrhosis patients. The future evaluation of the gut-microbiota-liver metabolic network and the intervention of these relationships using probiotics, synbiotics, and prebiotics, with sufficient nutrition could aid the development of treatments and prevention for liver cirrhosis patients.
肠道微生物群有能力产生多种化合物,这些化合物在调节远端器官的活动中起主要作用,而肝脏位于肠道下游的关键位置。与肠道微生物群相关的化合物,如短链脂肪酸、胆汁酸、胆碱代谢物、吲哚衍生物、维生素、多胺、脂质、神经递质和神经活性化合物,以及下丘脑 - 垂体 - 肾上腺轴激素,具有多种生物学功能。本综述聚焦于肝硬化中的肠道微生物群与宿主代谢。肝硬化中的微生物群失调会导致严重并发症,如菌血症和肝性脑病,同时伴有小肠细菌过度生长和肠道通透性增加。本文对肝硬化中的肠道菌群失调以及临床环境中益生菌和合生元的干预进行了综述和评估。最近的研究揭示了慢性代谢性肝病中肠道微生物群与宿主代谢之间的关系,特别是非酒精性脂肪性肝病、酒精性肝病,以及与糖尿病和肥胖等微生物群失调相关代谢疾病中的肠道微生物群代谢相互作用。最近,我们对肠道与肝脏之间的关系以及这种关系如何调节肝硬化中的全身代谢变化的理解有所增加。肝硬化患者血清中的磷脂、游离脂肪酸、多不饱和脂肪酸水平,尤其是二十碳五烯酸、花生四烯酸和二十二碳六烯酸水平与特定的粪便菌群有显著相关性。许多临床和实验报告都支持脂肪酸代谢与肠道微生物群之间的关系。在接受益生菌治疗的肝硬化患者中,各种血液代谢组,如细胞因子、氨基酸和维生素,都与肠道微生物群相关。未来对肠道微生物群 - 肝脏代谢网络的评估以及使用益生菌、合生元和益生元对这些关系进行干预,并提供充足的营养,可能有助于开发针对肝硬化患者的治疗和预防方法。